Day: October 22, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Quantexa Recognized as Category Leader in the RiskTech Quadrant® for KYC Solutions

Quantexa earned a top ranking in the RiskTech100® 2025 Report, highlighting its strength and innovation in the expanding risk technology and compliance market LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) — Quantexa, a leading provider of Decision Intelligence solutions for public and private sectors, today announced it has received recognition in

Arrivée des combattants Wazalendo en Ituri « pour neutraliser les ADF »

Une dizaine de combattants Wazalendo, venus du Nord-Kivu, sont installés depuis samedi 19 octobre vers Mungamba à environ 100 kilomètres de la ville de Bunia dans le territoire d’Irumu en Ituri. D’après des sources locales, ce premier groupe est venu inspecter la région en prévision de l’installation de leur campement